SCHEMBL10237758

SCHEMBL10237758

Cc1ccc2c(c1)C(=O)/C(=C/O)C(C)(CCCO[Si](C)(C)C(C)(C)C)O2

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.33
ATM Q13315 2/20 0.33
RAD52 P43351 1/20 0.33
DUT P33316 1/20 0.32
STK17B O94768 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8515935 0.88 KDM4E (0.34) KDM4EDUTSTK17B
SCHEMBL8515932 0.88 KDM4E (0.34) KDM4EDUTSTK17B
SCHEMBL8515929 0.88 KDM4E (0.34) KDM4EDUTSTK17B
SCHEMBL10237755 0.82 ATM (0.33) KDM4EATMRAD52DUT
SCHEMBL10237757 0.75 AKT1 (0.47) KDM4EATMRAD52DUT
SCHEMBL874944 0.71 DUT (0.32) DUT
SCHEMBL874288 0.71 PPIB (0.33) KDM4EDUTSTK17B
SCHEMBL873832 0.64 AKT1 (0.49) KDM4EATMRAD52DUT
SCHEMBL891554 0.63 DUT (0.32) DUT
SCHEMBL10237756 0.63 KDM4E (0.38) KDM4EATMRAD52STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES GENENTECH, INC. 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 KDM4E 3940/4885ATM 3827/4885RAD52 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.